NHIF Published Research

Latest Article

Rate of Discontinuation from Home Infusion Therapy Due to Adverse Drug Reactions and Unplanned Hospitalizations – A Pilot Study

NHIF Research Rate of Discontinuation from Home Infusion Therapy Due to Adverse Drug Reactions and Unplanned Hospitalizations – A Pilot Study September/October 2021 By Danell J. Haines, PhD and Michelle Simpson, PharmD, BCSCP Abstract Background: Existing for more than 4 decades, the home and specialty infusion industry is well established. In 2019 alone more than 3.2 million patients were served.1

Read More »

Publications

March/April 2021 Research Supplement
  • Discharge Reasons of Patients Receiving Home-Based Outpatient Parenteral Antimicrobial Therapy
  • A Home Infusion Program for Administration of Bamlanivimab in High-Risk Settings
Additional Articles

Over the first two years, our patient satisfaction study reviewed data collected from a sample of more than 32,000 home infusion patients and over 6,000 completed surveys.  Key findings include that patients are overwhelmingly satisfied with their home infusion experience and that patients receiving biologic therapies report the highest rates of satisfaction among all therapy categories.

Organizations that utilize the standardized NHIF patient satisfaction survey tool can compare performance to national standards. The data includes 12 questions with 22 data points based on the NHIF Uniform Patient Satisfaction Survey Questions published in 2017, which cover the essential elements of services when patients receive infusions in the home setting.

NHIA REPORT ON BAMLANIVIMAB PILOT PROGRAM AND ADMINISTRATION OF BAMLANIVIMAB IN HIGH-RISK SETTINGS (Feb 2021)

NHIA partnered with the Department of Health and Human Services (HHS) to launch our Bamlanivimab Pilot Program, to facilitate the administration of bamlanivimab in long-term care facilities. This program is part of HHS’s Special Projects for Equitable and Efficient Distribution (SPEED). Learn more about the program, patient demographics, costs, clinical outcomes, and more. Access the report now.​